Helmholtz Gemeinschaft

Search
Browse
Statistics
Feeds

Diagnosis of preeclampsia with soluble Fms-like tyrosine kinase 1/placental growth factor ratio: an inter-assay comparison

Item Type:Article
Title:Diagnosis of preeclampsia with soluble Fms-like tyrosine kinase 1/placental growth factor ratio: an inter-assay comparison
Creators Name:Andersen, L.B. and Frederiksen-Møller, B. and Work Havelund, K. and Dechend, R. and Jørgensen, J.S. and Jensen, B.L. and Nielsen, J. and Lykkedegn, S. and Barington, T. and Christesen, H.T.
Abstract:The angiogenic factor ratio soluble Fms-kinase 1 (sFlt-1)/placental growth factor (PlGF) is a novel diagnostic tool for preeclampsia. We compared the efficacy of the KRYPTOR (BRAHMS) automated assays for sFlt-1 and PlGF with the Elecsys (Roche) assays in a routine clinical setting. Preeclamptic women (n = 39) were included shortly after the time of diagnosis. Normotensive control pregnancies were matched by gestational age (n = 76). The KRYPTOR assays performed comparably or superior to Elecsys (sFlt-1/PlGF area under the curve 0.746 versus 0.735; P = .09; for non-obese 0.820 versus 0.805, P = .047). For early-onset preeclampsia, KRYPTOR area under the curve increased to 0.929 with a 100% specificity for preeclampsia at cut-off 85 and an 88.9% sensitivity for preeclampsia at cut-off 33. For women with preeclampsia and preterm delivery or Hemolysis, Elevated Liver enzymes, Low Platelet count (HELLP) syndrome, the KRYPTOR sFlt-1/PlGF ratio was manifold increased (P < .01). The sFlt-1/PlGF ratio proved especially useful in early-onset preeclampsia, preeclampsia with preterm delivery or HELLP, and among non-obese women.
Keywords:Hypertension, Obesity, Pregnancy, HELLP Syndrome
Source:Journal of the American Society of Hypertension
ISSN:1933-1711
Publisher:Elsevier
Volume:9
Number:2
Page Range:86-96
Date:February 2015
Official Publication:https://doi.org/10.1016/j.jash.2014.11.008
PubMed:View item in PubMed

Repository Staff Only: item control page

Open Access
MDC Library